Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
189
Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression

- The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, targeting cancer drug resistance and immune suppression.
- Kairos Pharma’s lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments.
- ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646, in combination with Apalutamide) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110, in combination with Osimertinib).
- The company is working with PreCheck Health Services to develop companion biomarkers for ENV-105, with the aim of identifying patients who will benefit most from being administered the drug candidate.
- Kairos is uniquely positioned to capitalize on the immunotherapy market, expected to reach $148 billion by 2030, as well as on the $11.3 billion prostate cancer market and the $14 billion EGFR-driven lung cancer market.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, is dedicated to advancing innovative oncology therapies to overcome critical challenges in cancer drug resistance and immune suppression, two significant challenges to effective cancer treatment. With an extensive intellectual property portfolio valid until 2035 to 2040, the company is developing a notable pipeline of drugs tackling cancer drug resistance with a focus on overcoming impacting widespread cancers, including prostate and lung cancer, as well as reversing immune suppression.

Kairos Pharma’s pipeline includes multiple candidates in different clinical and preclinical stages:

- ENV-105: An antibody that targets CD105 — a protein identified as a key driver of resistance to various cancer treatments, this lead candidate is currently in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646 in combination with Apalutamide to overcome anti-androgen resistance) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110 in combination with Osimertinib to address resistance).
- KROS-201: In the preclinical stage with preparation for a Phase 1 trial, this drug candidate targets glioblastoma and works by activating external T cells to target and destroy tumor cells. This candidate has received Investigational New Drug (“IND”) clearance from the Food and Drug Administration.
- KROS-101: In the preclinical stage, this drug candidate is designed to complement existing immunotherapies, showing promise in enhancing the immune system’s response by increasing the number and efficiency of T cells.
- KROS-102: In the preclinical stage, this drug candidate targets autoimmune diseases and works by decreasing T cell activity.
- KROS-301 and KROS-401: In the preclinical stage, both of these candidates focus on inhibiting cancer cell growth and tackling immune suppression in cancers such as triple-negative breast cancer.
- ENV-205: In the preclinical stage, this antibody targets Mitochondrial DNA with the goal of reversing resistance to chemotherapy in prostate cancer and others.

To achieve more accurate patient screening and monitoring for the ENV-105 Phase 1 and Phase 2 clinical trials, the company recently sealed a strategic agreement with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing (https://nnw.fm/dacoc ).

Under the terms of the partnership, PreCheck Health will focus on developing companion biomarkers for ENV-105, with the aim of advancing cancer treatment by identifying patients who will benefit most from being administered Kairos’s drug candidate. The two companies will utilize advanced molecular diagnostics to corroborate and further develop biomarkers previously identified in a Phase 2 clinical trial, with the goal of predicting patient responses to ENV-105 prior to treatment, in order to offer a more personalized approach to cancer care. The collaboration will rely on PreCheck’s proprietary SolidTumorCheck+ platform, which allows for gene expression profiling of tumor biopsies.

“This collaboration is an exciting step forward for Kairos Pharma. By working with PreCheck Health Services, we are advancing our mission to provide personalized cancer treatment solutions,” said Dr. John Yu, Kairos Pharma’s CEO. “The biomarkers we develop will enable us to tailor therapies to individual patients, improving their chances of a successful response to ENV105.”

The company also attended two major industry events in October, to discuss its drug development efforts and extensive pipeline. First, Dr. Yu participated in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he spoke with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group (https://nnw.fm/q5FaM ). The summit was held virtually on Oct. 15 – 17. The Kairos Pharma CEO also presented a corporate overview at the LD Micro Main Event XVII, held on Oct. 28 – 30 in Los Angeles (https://nnw.fm/YINv8 ).

With its innovative technologies to reverse key mechanisms of drug resistance and immune suppression of cancer and addressing underserved areas in cancer treatment, Kairos Pharma is strongly positioned to capitalize on the cancer therapy and immunotherapy markets by meeting substantial unmet needs. With ENV-105 in particular, the company has significant potential to capture a portion of the prostate cancer market, estimated at $11.3 billion, and the EGFR-driven lung cancer market, valued at $14 billion. The immunotherapy market, estimated to reach up to $148 billion by 2030, represents another major growth area for Kairos Pharma.

For more information, visit the company’s website at www.KairosPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

Kairos Pharma Ltd. (KAPA) Stock Research Links

KAPA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 116

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 174

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 9

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 73

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 160

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 40

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading

Top 5 Most Recently Viewed Articles

Fujitsu Enhances ETF Trading with New ASX Partnership

Updated Category News Views 212

Fujitsu Partners with ASX for ETF Trading Innovation Fujitsu Limited is teaming up with the Australian Securities Exchange (ASX) and the Tokyo Stock Exchange (TSE) to create a state-of-the-art SaaS-based Request for Quote (RFQ) platform. This exciting initiative represents a significant step forward in modernizing the ETF trading landscape. Understanding the New RFQ...

Continue Reading
Owens Corning Reports Strong Earnings and Future Outlook

Updated Category News Views 177

Owens Corning Shows Strong Performance in Recent Quarter Owens Corning (NYSE: OC) has exceeded expectations with its recent earnings results, garnering significant attention from investors. The company reported exceptionally strong numbers from its latest earnings announcement, which prompted a notable increase in its stock price. The performance indicates solid...

Continue Reading
Research Links Chorioamnionitis to Preterm Birth Developments

Updated Category News Views 182

Chorioamnionitis and Its Impact on Early Birth Recent research emphasizes the severe implications of moderate to severe chorioamnionitis (HCA) associated with preterm births. Experts from Cincinnati Children's Hospital have confirmed that these infections not only trigger preterm deliveries but also lead to significant neurodevelopmental issues in early childhood. Study...

Continue Reading
Micron Shifts Focus: Exiting Consumer Market for AI Future

Updated Category News Views 305

Micron Technology's Significant Move Micron Technology, Inc. (NASDAQ: MU) has announced a strategic decision to exit its Crucial consumer business, ceasing the sale of Crucial-branded products through various global retailers and distributors. This transition marks a significant pivot aimed at refocusing efforts toward emerging market opportunities, especially in...

Continue Reading
China's COMAC Strives for Growth in Vietnam's Aviation Sector

Updated Category News Views 449

China's Ambitious Move into Vietnam's Aviation Market China's state-owned aircraft manufacturer, COMAC, is making significant strides to penetrate the international aviation market. The focus is currently on gaining approval for its C909 jets in Vietnam, a move indicative of a broader strategy to enhance its global presence. This initiative highlights the ongoing...

Continue Reading